De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Rhinomed Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Michael Johnson

Algemeen directeur

AU$531.6k

Totale compensatie

Percentage CEO-salaris	69.8%
Dienstverband CEO	11yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Michael Johnson's beloning veranderd ten opzichte van Rhinomed's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	AU$532k	AU$371k	-AU$11m
Mar 31 2023	n/a	n/a	-AU$9m
Dec 31 2022	n/a	n/a	-AU$7m
Sep 30 2022	n/a	n/a	-AU$6m
Jun 30 2022	AU$369k	AU$301k	-AU$5m
Mar 31 2022	n/a	n/a	-AU$6m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$8m
Jun 30 2021	AU$2m	AU$304k	-AU$9m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	n/a	n/a	-AU$7m
Sep 30 2020	n/a	n/a	-AU$7m
Jun 30 2020	AU$1m	AU$304k	-AU$7m
Mar 31 2020	n/a	n/a	-AU$8m
Dec 31 2019	n/a	n/a	-AU$8m
Sep 30 2019	n/a	n/a	-AU$7m
Jun 30 2019	AU$748k	AU$305k	-AU$6m
Mar 31 2019	n/a	n/a	-AU$5m
Dec 31 2018	n/a	n/a	-AU$5m
Sep 30 2018	n/a	n/a	-AU$5m
Jun 30 2018	AU$363k	AU$255k	-AU$4m
Mar 31 2018	n/a	n/a	-AU$4m
Dec 31 2017	n/a	n/a	-AU$5m
Sep 30 2017	n/a	n/a	-AU$5m
Jun 30 2017	AU$672k	AU$231k	-AU$4m

Compensatie versus markt: De totale vergoeding ($USD 347.11K ) Michael } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 313.13K ).

Compensatie versus inkomsten: De vergoeding van Michael is gestegen terwijl het bedrijf verliesgevend is.

CEO

Michael Johnson

11yrs

Tenure

AU$531,600

Compensatie

Mr. Michael Johnson serves as the Chief Executive Officer, Managing Director and Executive Director of Rhinomed Limited (formerly, Consegna Group Limited) since February 1, 2013. Mr. Johnson serves as a Di...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Johnson	CEO, MD & Executive Director	11yrs	AU$531.60k	0.64% A$ 73.9k
Ross MacDonald	Member of the Medical Advisory Board	no data	geen gegevens	geen gegevens
Ronald Dewhurst	Independent Non-Executive Chairman	8.2yrs	AU$110.00k	6.88% A$ 792.3k
Steve Harris	Member of the Medical Advisory Board	no data	geen gegevens	geen gegevens
Lynette Swinburne	Non-Executive Director	1.4yrs	AU$58.45k	0.062% A$ 7.1k
John McBain	Non-Executive Director	2.8yrs	AU$73.33k	18.43% A$ 2.1m

5.5yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van RNO wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

Rhinomed Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Less than half of directors are independent

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Less than half of directors are independent

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Less than half of directors are independent

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Less than half of directors are independent

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

Less than half of directors are independent

New major risk - Market cap size

Less than half of directors are independent

Insider recently bought AU$242k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Insider recently bought AU$372k worth of stock

Less than half of directors are independent

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur